Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 7, 2012, Pages 759-801

  Carradori, Simone ^a   Secci, Daniela ^a   Bolasco, Adriana ^a   Chimenti, Paola ^a   D'Ascenzio, Melissa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Depression; Dual inhibitors; MAO inhibitors; Neuroprotection; Parkinson's disease

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 3 FLUORO 7 (2,2,2 TRIFLUOROETHOXY)PHENOXATHIIN 10,10 DIOXIDE; AMIDE; AZABENZOTHIAZOLE DERIVATIVE; AZABENZOXAZOLE DERIVATIVE; BENZOFURAN DERIVATIVE; CHROMONE DERIVATIVE; CLORGYLINE; COUMARIN DERIVATIVE; CX 157; CYCLOPROPANE DERIVATIVE; DONEPEZIL; HLA 20; ISOXAZOLE DERIVATIVE; LEVODOPA; LINEZOLID; MONOAMINE OXIDASE INHIBITOR; ORIGANUM VULGARE EXTRACT; OXAZOLIDINONE DERIVATIVE; PARGYLINE; PLANT EXTRACT; PROPARGYLAMINO DERIVATIVE; RASAGILINE; RIVASTIGMINE; SAFINAMIDE; SELEGILINE; TACRINE; TEDIZOLID; TRANYLCYPROMINE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALCOHOLISM; ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; BRAIN SPONGIOSIS; CENTRAL NERVOUS SYSTEM DISEASE; CYTOTOXICITY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IC 50; INSOMNIA; IRON CHELATION; ISCHEMIA; MAJOR DEPRESSION; NEUROPROTECTION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OREGANO; PARKINSON DISEASE; PATENT; PROSTATE CANCER; REPERFUSION INJURY; REVIEW; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; THROMBOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOBACCO DEPENDENCE;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MENTAL DISORDERS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEURODEGENERATIVE DISEASES; PATENTS AS TOPIC;

EID: 84862867905     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.698613     Document Type: Review

References (117)

1. Edmondson DE, Binda C, Wang J, et al. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry 2009;48:4220-30
2. Shih JC, Wu JB, Chen K. Transcriptional regulation and multiple functions of MAO genes. J Neural Transm 2011;118:979-86
3. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: Risks, benefits, and lore. Cleve Clin J Med 2010;77:859-78
4. Youdim MBH, Edmondson D, Tipton KF. the therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006;7:295-309
5. Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: From pathophysiology to therapeutics. Adv Drug Deliv Rev 2008;60:1527-33
6. Mallajosyula JK, Kaur D, Chinta SJ, et al. MAO-B elevation in mouse brain astrocytes results in Parkinsons pathology. PLoS One 2008;3:e1616
7. Bolasco A, Fioravanti R, Carradori S. Recent development of monoamine oxidase inhibitors. Expert Opin Ther Patents 2005;15:1763-82
8. Bolasco A, Carradori S, Fioravanti R. Focusing on new monoamine oxidase inhibitors. Expert Opin Ther Patents 2010;20:909-
9. Son SY, Ma J, Kondou Y, et al. Structure of human monoamine oxidase A at 2.2-A resolution: The control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA 2008;105:5739-44.Data deposition www. pdb.org; PDB ID code2Z5X
10. Binda C, Aldeco M, Geldenhuys WJ, et al. Molecular insights into human monoamine oxidase B inhibition by the glitazone antidiabetes drugs. ACS Med Chem Lett 2012;3:39-42
11. Prins LH, Petzer JP, Malan SF. Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem 2010;45:4458-66
12. Chimenti F, Secci D, Bolasco A, et al. Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines. J Med Chem 2010;53:6516-20
13. Chimenti F, Secci D, Bolasco A, et al. Investigations on the 2-thiazolylhydrazyne scaffold: Synthesis and molecular modeling of potent and selective human monoamine oxidase inhibitors. Bioorg Med Chem 2010;18:5715-23
14. Chimenti F, Secci D, Bolasco A, et al. Synthesis and selective inhibition of human monoamine oxidases of a large scaffold of (4,5-substituted-thiazol-2- yl) hydrazones. Med Chem Commun 2010;1:61-72
15. Chimenti F, Secci D, Bolasco A, et al. Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem 2010;18:5063-70
16. Chimenti F, Maccioni E, Secci D, et al. Synthesis, stereochemical identification and selective inhibitory activity against hMAO-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones. J Med Chem 2008;51:4874-80
17. Catto M, Nicolotti O, Leonetti F, et al. Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligandand target-based approaches. J Med Chem 2006;49:4912-25
18. Carotti A, Altomare C, Catto M, et al. Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins. Chem Biodivers 2006;3:134-49
19. Secci D, Bolasco A, Chimenti P, Carradori S. the state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/ anticonvulsant agents. Curr Med Chem 2011;18:5114-44
20. Bonivento D, Milczek EM, McDonald GR, et al. Potentiation of ligand binding through cooperative effects in monoamine oxidase B. J Biol Chem 2010;285:36849-56
21. Wang Y, Liu J, Zhu Q. 2-Phenylselenomethyl-2,3-dihydrobenzofuran as monoamine oxidase inhibitor and its preparation. CN102250048; 2011
22. Wang Y. Preparation of 2,3-dihydrobenzofuran derivatives as monoamine oxidase inhibitors. CN102267990; 2011
23. Kudrin AN, Zaidler II. Search for compounds with antiarrhythmic activity among the derivatives of selenophene, amines of the acetylene series, beta-aminoketones, aminopyrazoles, monoamino oxidase inhibitors. Farmakol Toksikol 1968;31:41-4
24. Korenevich NN. On the problem of the treatment of acute experimental pancreatitis with a drug of the selenophene class and the monoaminoxidase inhibitor vetrazine. Klin Khir 1966;4:34-9
25. Wang Y, Li Q. Preparation of 2-methylbenzofuran compounds as monoamine oxidase inhibitors. CN102267989; 2011
26. Wang Y. Preparation of isoxazole containing 2-methylbenzofuran derivatives as monoamine oxidase inhibitors. CN102229606; 2011
27. Wang Y. Preparation of 1,2,3-triazole containing 2-methylbenzofuran compounds as monoamine oxidase inhibitors. CN102229603; 2011
28. Chimenti F, Secci D, Bolasco A, et al. Synthesis, molecular modelling and selective inhibitory activity against human monoamine oxidases of 3-carboxamido substituted coumarins. J Med Chem 2009;52:1935-42
29. Secci D, Carradori S, Bolasco A, et al. Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives. Eur J Med Chem 2011;46:4846-52
30. Chimenti F, Secci D, Bolasco A, et al. Inhibition of monoamine oxidases by coumarin-3-acyl derivatives: biological activity and computational study. Bioorg Med Chem Lett 2004;14:3697-703
31. Santana L, Uriarte E, Gonzalez-Diaz H, et al. A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J Med Chem 2006;49:1149-56
32. Santana L, Gonzalez-Diaz H, Quezada E, et al. Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem 2008;51:6740-51
33. Matos MJ, Vina D, Quezada E, et al. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett 2009;19:3268-70
34. Matos MJ, Vina D, Picciau C, et al. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett 2009;19:5053-5
35. Matos MJ, Vina D, Janeiro P, et al. New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett 2010;20:5157-60
36. Vina D, Matos MJ, Ferino G, et al. 8-Substituted 3-arylcoumarins as potent and selective MAO-B inhibitors: Synthesis, pharmacological evaluation, and docking studies. ChemMedChem 2012;7:464-70
37. Universidade de Santiago de Compostela. Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparacion de nuevos derivados. EP2343347; 2010
38. Yanez M, Fraiz N, Cano E, Orallo F. Inhibitory effects of cis- and trans resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Commun 2006;344:688-95
39. Matos MJ, Teran C, Perez-Castillo Y, et al. Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. J Med Chem 2011;54:7127-37
40. Alcaro S, Gaspar A, Ortuso F, et al. Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B. Bioorg Med Chem Lett 2010;20:2709-12
41. Gaspar A, Silva T, Yanez M, et al. Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors. J Med Chem 2011;54:5165-73
42. Gaspar A, Reis J, Fonseca A, et al. Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett 2011;21:707-9
43. Gaspar A, Teixeira F, Uriarte E, et al. Towards the discovery of a novel class of monoamine oxidase inhibitors: Structure-property-activity and docking studies on chromone amides. ChemMedChem 2011;6:628-32
44. Universidade do Porto. Utilizacao de cromonas, seus derivados, seus sais farmaceuticamente aceitaveis e seus pro-farmacos com actividade inibidora da monoamina oxidase e aplicacoes terapeuticas relacionadas. PT104487; 2010
45. Zhu Q, Jia C. Method for high-throughput screening of benzotriazole inhibitors of monoamine oxidase via click chemistry. CN101881733; 2010
46. Dostert P, Strolin-Benedetti M, Guffroy C. Different stereoselective inhibition of monoamine oxidase-B by the R- and S-enantiomers of MD 780236. J Pharm Pharmacol 1983;35:161-5
47. Gates KS, Silverman RB. Model studies for the mechanism of inactivation of monoamine oxidase by 5-aminomethyl-3-aryl-2-oxazolidinones. J Am Chem Soc 1989;111:8891-5
48. Hauck SI, Cederberg C, Doucette A, et al. New carbon-linked azole oxazolidinones with improved potency and pharmacokinetics. Bioorg Med Chem Lett 2007;17:337-40
49. Park C-H, Brittelli DR, Wang CL, et al. Antibacterials. Synthesis and structure-activity studies of 3-aryloxooxazolidines. 4. Multiply-substituted aryl derivatives. J Med Chem 1992;35:1156-65
50. Legochem Bioscience, Ltd. Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof. WO2010036000; 2010
51. Binda C, Aldeco M, Mattevi A, Edmondson DE. Interactions of monoamine oxidases with the antiepileptic drug zonisamide: Specificity of inhibition and structure of the human monoamine oxidase B complex. J Med Chem 2011;54:909-12
52. Shader RI, Greenblatt DJ. the reappearance of a monamine oxidase inhibitor (isocarboxazid). J Clin Psychopharmacol 1999;19:105-6
53. SK Holdings Co., Ltd. Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson disease using the same. WO2010098600; 2010
54. Zhu Q, Song M. Amides as monoamine oxidase inhibitor and their preparation. CN101982170; 2011
55. Kaiser C, Lester BM, Zirkle CL, et al. 2-Substituted cyclopropylamines. I. Derivatives and analogs of 2-phenylcyclopropylamine. J Med Chem 1962;5:1243-65
56. Zirkle CL, Kaiser C, Tedeschi DH, et al. 2-Substituted cyclopropylamines. II. Effect of structure upon monoamine oxidase-inhibitory activity as measured in vivo by potentiation of tryptamine convulsions. J Med Chem 1962;5:1265-84
57. Gooden DM, Schmidt DMZ, Pollock JA, et al. Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B. Bioorg Med Chem Lett 2008;18:3047-51
58. Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use. WO2011042217; 2011
59. Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use. WO2010084160; 2010
60. McCafferty DG, Pollock J. Arylcyclopropylamines and method of use. US20100324147; 2010
61. Merz Pharma GmbH & Co. Metabotropic glutamate receptor modulators. WO2011015343; 2011
62. Merck Sharp & Dhome Corp. Novel substituted azabenzoxazoles. WO2010051196; 2010
63. Gordeev MF, Yuan Z, Liu J, Wang Q. Antimicrobial indoline compounds for treatment of bacterial infections. US20100069441; 2010
64. Bar-Am O, Amit T, Weinreb O, et al. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: Involvement of MAPK and PKC activation. J Alzheimers Dis 2010;21:361-71
65. Zhu Q, Jia C. Application of propargylimine-series compound in preparation of monoamine oxidase inhibitor. CN101703501; 2010
66. Decker M. Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties. Mini Rev Med Chem 2007;7:221-9
67. Consejo Superior de Investigaciones Cientificas (CSIC) Universidad Autonoma de Barcelona. New derivatives of propargylamine having neuroprotective capacity for the treatment of Alzheimers and Parkinsons diseases. WO2011113988; 2011
68. Ellman GL, Courtney KD, Andres V Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-90
69. Fowler CJ, Tipton KF. Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem Pharmacol 1981;30:3329-32
70. Galimberti D, Scarpini E. Alzheimers disease: From pathogenesis to disease-modifying approaches. CNS Neurol Disord Drug Targets 2011;10:163-74
71. Castellani RJ, Moreira PI, Perry G, Zhu X. the role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors 2012;38:133-8
72. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimers disease brain: Central role for amyloid beta-peptide. Trends Mol Med 2001;7:548-54
73. Youdim MB. M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models. Parkinsonism Relat Disord 2012;18:S151-4
74. Kupershmidt L, Weinreb O, Amit T, et al. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience 2011;189:345-58
75. Varinel, Inc. Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof. WO2012020389; 2012
76. Tipton KF, McCrodden JM, Kalir AS, Youdim MB. Inhibition of rat liver monoamine oxidase by alpha-methyland N-propargyl-amine derivatives. Biochem Pharmacol 1982;31(7):1251-5
77. Yeda Research and Development Co., Ltd, Technion Research and Development Foundation, Ltd. Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them. WO2010086860; 2010
78. Mechan AO, Fowler A, Seifert N, et al. Monoamine reuptake inhibition and mood-enhancing potential of a specified oregano extract. Br J Nutr 2011;105:1150-63
79. DSM IP Assets B.V. Oregano extract and its components for enhancing vigilance. US20110070326; 2011
80. Elan Pharma Int., Ltd. Drug delivery composition. WO2011029598; 2011
81. Robinson DS, Amsterdam JD. the selegiline transdermal system in major depressive disorder: A systematic review of safety and tolerability. J Affect Disord 2008;105:15-23
82. Labtech GmbH. Transdermal patch formulation. WO2011029598; 2011
83. Fowler JS, Logan J, Azzaro AJ, et al. Reversible inhibitors of monoamine oxidase-A (RIMAs): Robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology 2010;35:623-31
84. Cenerx Biopharma, Inc. Oral antidepressant formulation with reduced excipient load. WO2011096953; 2011
85. Cenerx Biopharma, Inc. Oral sustained release antidepressant formulation. WO2010080977; 2010
86. Cenerx Biopharma, Inc. Oral enteric antidepressant formulation. WO2010080970; 2010
87. Merck patent GMBH. Novel polymorphic forms of (S)-2-[4-(3- fluorobenzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof. WO2011047767; 2011
88. Binda C, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs. J Med Chem 2007;50:5848-52
89. Lohle M, Reichmann H. Controversies in neurology: Why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinsons disease. BMC Neurol 2011;11:112-18
90. Hauser RA. New considerations in the medical management of early Parkinsons disease: Impact of recent clinical trials on treatment strategy. Parkinsonism Relat Disord 2009;15:S17-21
91. McDonald A, Tipton K, OSullivan J, et al. Modelling the roles of MAO and SSAO in glucose transport. J Neural Transm 2007;114:783-6
92. Uceyler N, Hauser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008;59:1279-98
93. Flamand V, Zhao H, Peehl DM. Targeting monoamine oxidase A in advanced prostate cancer. J Cancer Res Clin Oncol 2010;136:1761-71
94. Ajou KT, Dilda P, Aumond P, et al. Increase of monoamine oxidase-B activity in the brain of scrapie-infected hamsters. Neurochem Int 2008;52:1416-21
95. Lewis A, Miller JH, Lea RA. Monoamine oxidase and tobacco dependence. Neurotoxicology 2007;28:182-95
96. Kaludercic N, Carpi A, Menabo R, et al. Monoamine oxidase (MAO) in the pathogenesis of heart failure and ischemia/riperfusion injury. Biochim Biophys Acta 2011;1813:1323-32
97. White TA, Kwon EM, Fu R, et al. the monoamine oxidase A gene promoter repeat and prostate cancer risk. Prostate 2012. [Epub ahead of print]
98. Sviglin KN, Nedic G, Nikolac M, et al. Insomnia, platelet serotonin and platelet monoamine oxidase in chronic alcoholism. Neurosci Lett 2011;500:172-6
99. Arrojo M, Baca-Garcia E, Perez-Rodriguez MM, et al. Platelet monoamine oxidase activity in obsessive-compulsive disorder. Eur Psychiatry 2007;22:525-9
100. Novaroli L, Daina A, Favre E, et al. Impact of species-dependent differences on screening, design, and development of MAO B inhibitors. J Med Chem 2006;49:6264-72
101. Mechlovich D, Amit T, Mandel SA, et al. the novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage. J Pharmacol Exp Ther 2010;333:874-82
102. Gosforth Centre (Holdings) PTY Ltd. Compositions and methods for treating neurodegenerative disorders. WO2011143721; 2011
103. Columbia Northwest Pharmaceuticals, LLC. Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients. WO2011119227; 2011
104. Alexander Vuckovic, MD, LLC. Compositions and methods for treating depression. WO2011100550; 2011
105. Celerx Biopharma, Inc. Method of treatment of androgen-mediated cancers. WO2012018759; 2012
106. Oryzon Genomics, S.A. Inhibitors for antiviral use. WO2011106105; 2011
107. Roquette Freres. Use of polysaccharides for treating stress and anxiety. WO2011077063; 2011
108. Caliper Life Science, Inc. Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions. WO2011069051; 2011
109. Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors. US20110098265; 2011
110. Synosia Therapeutic, Inc. Methods for treating dependence. WO2010124089; 2010
111. Rao SG, Gendreau MR, Dedhiya MG. Methods of managing fibromyalgia using. US20100197797; 2010
112. Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center. Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical. WO2010085452; 2010
113. Concert Pharmaceuticals, Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological disease, intractable and chronic pain and brain injury. WO2010062692; 2010
114. Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole. WO2010022140; 2010
115. Phytopharm PLC. Treatment of L-Dopa, dopamine agonist and/or dopamine enhancer induced disorders. WO2010010896; 2010
116. Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization. US20100168119; 2010
117. the Procter & Gamble Co. the use of monoamine oxidase inhibitors to improve epithelial biology. WO2012051374; 2012